IngredientesGlycosaminoglycans (GAGs), historically termed mucopolysaccharides, are a family of long, unbranched, negatively charged polysaccharide compounds that are ubiquitous in animal tissues. Glycosaminoglycans (GAGs), also known as mucopolysaccharides, are negatively-charged polysaccharide compounds composed of repeating disaccharide units that are present in every mammalian tissue. The glycosaminoglycans are historically referred to as the mucopolysaccharides given that they were originally characterized in mucus membranes and mucosal exudates.
The GAG molecules are long unbranched polysaccharides containing a repeating disaccharide unit. The disaccharide units contain either of two modified sugars, N-acetylgalactosamine (GalNAc) or N-acetylglucosamine (GlcNAc), and a uronic acid such as glucuronate (GlcA) or iduronate (IdoA) or a galactose residue. GAGs are highly negatively charged molecules, with extended conformation that imparts high viscosity to the solution in which they reside. GAGs are located primarily on the surface of cells or in the extracellular matrix (ECM) but are also found in secretory vesicles in some types of cells. Along with the high viscosity of GAGs comes low compressibility, which makes these molecules ideal for a lubricating fluid in the joints.
The four primary groups of GAGs are classified based on their core disaccharide units and include heparin/heparan sulfate, chondroitin sulfate/dermatan sulfate, keratan sulfate, and hyaluronic acid. Each class has distinct structural features and physiological roles:
Glycosaminoglycan structures have a high degree of heterogeneity (termed "fine structure") with respect to molecular weight, disaccharide construction, and sulfation.
Physiologically, glycosaminoglycans are organized in proteoglycans, formed by a protein core wherein the glycosaminoglycan is linked by a linkage region. These structures are in charge of the control of biochemical reactions by the uptake and the release of proteins and growth factors. Proteoglycans are the specific group of glycoproteins that have at least one glycosaminoglycan chain attached to the protein; categorization is typically by the GAG chain(s) present. Heparan/heparin sulfate and chondroitin sulfate are the most common GAGs contained by proteoglycans.
GAGs are produced endogenously in the human body but are also found abundantly in foods and are extracted from animal tissues for commercial supplement production.
Glycosaminoglycans (GAGs) are naturally occurring polysaccharides found abundantly in connective tissues, such as cartilage, skin, and the synovial fluid of joints. Natural sources of glycosaminoglycans include pig and beef intestinal mucosa, lung, spleen, pancreas, and a variety of other solid and parenchymal organs and tissues.
Commercially, the most important extractive sources are animal-derived. The glycosaminoglycans used in pharmaceutical preparations include unfractionated heparin, which is not dependent on the nature of the extractive source (porcine, bovine or ovine intestinal mucosa, lung, etc.); heparinic fractions and fragments of any molecular weight; dermatan sulfate, its fragments or fractions; and heparan sulfate, its fragments or fractions. Heparin is extracted from tissues of different origin: bovine or porcine intestinal mucosa, lung, etc. There are no dietary sources of glucosamine, and commercially available glucosamine is derived from shellfish.
Semi-synthetic sources have also been developed. Synthetic elaboration of a natural starting material which possesses much of the complexity of the desired material may be performed; examples of such natural starting materials are chitin and dextran, with synthetic steps including amide bond hydrolysis, oxidation, and sulfation.
GAGs are available in multiple forms as dietary supplements and pharmaceutical preparations:
The medicinal use of tissues rich in GAGs predates modern biochemistry by many centuries, although the molecules themselves were not identified until the twentieth century.
Historically, their medicinal use dates back to traditional remedies where animal cartilage and broths were consumed for joint health and overall vitality. Ancient medical systems, including those of China and Greece, recommended bone broths and animal trachea—rich in GAGs such as chondroitin sulfate and hyaluronic acid—as tonics for joint and skin concerns.
Traditional therapies dating back centuries often utilized animal cartilage or bone broths, which are rich in GAGs, to support joint health, ease inflammation, and accelerate recovery from injuries. Remedies such as boiled animal bones were commonly prescribed in ancient Chinese and Ayurvedic medicine to promote mobility and alleviate symptoms of arthritis and joint discomfort.
The study of proteoglycans dates back to the beginning of the 20th century with investigations of "chondromucoid" from cartilage and anticoagulant preparations from liver (heparin). From 1930 to 1960, great strides were made in analyzing the chemistry of the polysaccharides of these preparations (also known as "mucopolysaccharides"), yielding the structure of hyaluronan, dermatan sulfate, keratan sulfate, different isomeric forms of chondroitin sulfate, heparin, and heparan sulfate.
Unfractionated heparin (UFH) came into clinical use in the 1930s, making extracorporeal circulation and cardiovascular surgery possible. In the 20th century, chondroitin sulfate and hyaluronic acid, two prominent GAGs, gained recognition for their ability to support joint mobility, reduce discomfort, and promote cartilage repair. These compounds became integral to remedies for osteoarthritis and other degenerative conditions, offering a natural alternative to synthetic medications.
Historically, the function of GAGs was thought to be limited to cell hydration and structural scaffolding. However, evidence now suggests that GAGs play a key role in cell signaling, which modulates a wide range of biochemical processes. Some of these processes include regulation of cell growth and proliferation, promotion of cell adhesion, anticoagulation, and wound repair, among many more.
The primary structural roles of GAGs derive from their physicochemical properties. GAGs are highly negatively charged molecules, with extended conformation that imparts high viscosity to the solution in which they reside. This charge attracts water molecules, conferring extraordinary hydration capacity to tissues. The key molecule involved in skin moisture is hyaluronic acid, a glycosaminoglycan with a unique capacity to retain water molecules.
These large complex carbohydrate molecules are present in every mammalian tissue where they are known to bind and regulate a broad range of proteins involved in a myriad of physiological and pathological processes.
GAGs affect lipid metabolism, inflammation, cell attachment, migration, invasion, and differentiation. The glycosaminoglycans primarily involved in cellular signaling are heparan sulfate (HS)/heparin and chondroitin sulfate (CS)/dermatan sulfate (DS).
Chondroitin/dermatan sulfate GAGs (CSGAGs) have specific growth factor interactions. Dermatan sulfate interactions with fibroblast growth factors FGF-2 and FGF-7 have been implicated in cellular proliferation and wound repair, while interactions with hepatic growth factor/scatter factor (HGF/SF) activate the HGF/SF signaling pathway (c-Met) through its receptor. CSGAGs are important in providing support and adhesiveness in bone, skin, and cartilage. Other biological functions for which CSGAGs play critical roles include inhibition of axonal growth and regeneration in CNS development, roles in brain development, neuritogenic activity, and pathogen infection.
Anticoagulation using GAGs (such as heparin and dermatan sulfate) proceeds via their catalysis of inhibition of coagulant enzymes (a significant one being thrombin) by serine protease inhibitors (serpins) such as antithrombin III (AT) and heparin cofactor II (HCII). Binding of the serpins by the catalysts occurs through specific sequences along the linear carbohydrate chain of the glycosaminoglycan. Heparin acts by binding to AT via a pentasaccharide sequence, thus potentiating inhibition of a variety of coagulant enzymes. Heparin can also potentiate inhibition of thrombin by binding to the serpin HCII. Dermatan sulfate acts by specifically binding to HCII via a hexasaccharide sequence, thus potentiating only the inhibition of thrombin.
The hyaluronic acid precursor sugars, UDP-glucuronic acid and UDP-N-acetylglucosamine, are transported from the cytoplasm to the plasma membrane for further processing without sulfation, leading to the production of hyaluronic acid. All other GAGs require additional modification steps that occur in and around the Golgi apparatus, including sulfation of functional groups by the sulfate donor compound 3'-phosphoadenosine-5'-phosphosulfate (PAPS). The availability of PAPS for the sulfation of GAGs significantly affects the biosynthetic rate of production of sulfated GAGs.
The sulfated GAGs synthesized in the Golgi apparatus undergo covalent linkage to anchor proteins known as proteoglycans (PGs).
Glucosamine is a natural precursor of the cartilage extracellular matrix component glycosaminoglycan. It has been widely promulgated as a remedy for osteoarthritis (OA) on the basis that it might provide a substrate for matrix synthesis and repair. In vitro studies have shown that adding glucosamine sulfate (GS) to human chondrocytes results in increased proteoglycan synthesis.
The most extensively studied clinical application of GAGs is in the management of osteoarthritis (OA). Chondroitin sulfate and glucosamine (a GAG precursor) are the principal agents studied. Chondroitin sulfate (CS) is a glycosaminoglycan (GAG) and glucosamine is an aminosaccharide acting as a substrate for biosynthesis of GAG.
In terms of disease classification, chondroitin sulfate and related GAG-based compounds are often described as symptomatic slow-acting drugs for osteoarthritis (SYSADOAs). Symptomatic slow-acting drugs for osteoarthritis (SYSADOA) have been vastly studied and have generated considerable interest among clinicians. SYSADOAs are generally used as a ground therapy with the main rationale to reduce the consumption of nonsteroidal anti-inflammatory drugs (NSAIDs) and thus limit the related adverse events.
Glycosaminoglycans are long, linear polysaccharides comprised of repeating disaccharide units with pleiotropic biological functions, with the non-sulfated GAG hyaluronic acid (HA), and sulfated GAGs dermatan sulfate, chondroitin sulfate, heparan sulfate, keratan sulfate, and to a lesser extent heparin all being expressed in skin. Their ability to regulate keratinocyte proliferation and differentiation, inflammatory processes and extracellular matrix composition and quality demonstrates their critical role in regulating skin physiology. The water-binding properties of GAGs and structural qualities, particularly for HA, are crucial for maintaining proper skin form and hydration.
Aging reduces the production of proteoglycans and glycosaminoglycans (such as hyaluronic acid) in the skin, as well as cartilage. As a result, skin tissue weakens, losing its integrity, and the skin becomes dry, unable to retain enough moisture.
Despite its discovery almost 100 years ago, heparin is still a life-saving compound, crucial for procedures such as treatment of deep venous thrombosis (DVT), pulmonary embolism (PE), and acute coronary syndrome (ACS), as well as for anticoagulation in surgery, interventional cardiology, and hemodialysis. Heparin, the widely used pharmaceutical anticoagulant, has been in clinical use for well over half a century. Its introduction reduced clotting risks substantially and subsequent developments, including the introduction of low-molecular-weight heparin, made possible many major surgical interventions that today make heparin an indispensable drug.
The key function of keratan sulfate is as a structural component of cornea proteoglycans. An injectable solution containing chondroitin sulfate and sodium hyaluronate is approved by the FDA to protect the eye during cataract surgery.
Glycosaminoglycans (GAGs) are important for the occurrence of signaling molecules and maintenance of the microenvironment within the extracellular matrix (ECM) in living tissues. GAGs and GAG-based biomaterial approaches have been widely explored to promote in situ tissue regeneration and repair by regulating the wound microenvironment, accelerating re-epithelialization, and controlling ECM remodeling.
The effects of HA on wound healing are molecular-weight dependent. Studies show that high molecular weight HA exhibits anti-inflammatory cues, whereas low molecular weight HA can be pro-inflammatory. HA accumulates during the inflammatory phase of wound healing and regulates early inflammation by recruiting neutrophils, modulating fibroblast migration, cytokine synthesis, and phagocytosis of microbes. Studies have shown that low molecular weight HA interacts with VEGF to promote wound repair.
There has been a recent burgeoning of interest in heparin and related glycosaminoglycan (GAG) polysaccharides, such as chondroitin sulfates, heparan sulfate, and hyaluronate, as potential agents in various applications. This ability arises mainly from the ability of GAGs to interact with, and alter the activity of, a wide range of proteins. New developments in the application of heparin and related GAGs across diverse fields ranging from thrombosis and neurodegenerative disorders to microbiology and biotechnology have been reviewed. Notably, however, clinical evidence for GAG supplementation specifically in neurological contexts remains preliminary and largely preclinical at present.
The most rigorous and largest clinical evaluation of GAG supplementation (glucosamine and chondroitin sulfate) is the U.S. government-sponsored Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT). GAIT is the first multicenter clinical trial in the United States to test the effects of the dietary supplements glucosamine and chondroitin for treatment of knee osteoarthritis. The study tested whether glucosamine and chondroitin used separately or in combination are effective in reducing pain and improving functional ability in patients with knee osteoarthritis.
Primary GAIT findings (24 weeks): The trial randomly assigned 1,583 patients with symptomatic knee osteoarthritis to receive 1,500 mg of glucosamine daily, 1,200 mg of chondroitin sulfate daily, both glucosamine and chondroitin sulfate, 200 mg of celecoxib daily, or placebo for 24 weeks. Up to 4,000 mg of acetaminophen daily was allowed as rescue analgesia. Assignment was stratified according to the severity of knee pain (mild [N=1,229] vs. moderate-to-severe [N=354]). The primary outcome measure was a 20 percent decrease in knee pain from baseline to week 24.
Glucosamine and chondroitin sulfate alone or in combination did not reduce pain effectively in the overall group of patients with osteoarthritis of the knee. Exploratory analyses suggest that the combination of glucosamine and chondroitin sulfate may be effective in the subgroup of patients with moderate-to-severe knee pain.
GAIT 2-year extension (structural outcomes): A 24-month, double-blind, placebo-controlled study, conducted at nine sites in the United States ancillary to GAIT, enrolled 662 patients with knee OA who satisfied radiographic criteria. Patients continued to receive glucosamine 500 mg three times daily, CS 400 mg three times daily, the combination of glucosamine and CS, celecoxib 200 mg daily, or placebo over 24 months. Rates of adverse events were similar across treatment groups and no liver-related serious adverse event occurred.
Eight primary trials were included in the systematic review with a duration of at least 12 months. There was evidence of statistically significant improvements in joint space loss, pain, and function for glucosamine sulphate; however, the clinical importance of these differences was less clear. In two studies of glucosamine sulphate, both funded by the manufacturer (Rotta, Italy) of an oral powder product, the need for knee arthroplasty was reduced from 14.5% to 6.3% at 8 years' follow-up. For other preparations of glucosamine, chondroitin, and combination therapy, there was less evidence to support a clinical effect.
In 2017, the American Academy of Orthopaedic Surgeons published a clinical practice guideline on management of osteoarthritis of the hip that concluded that moderate-strength evidence does not support the use of glucosamine sulfate for hip osteoarthritis. This conclusion was based on the one high-quality study that was identified. This study, published in 2008, included 222 participants, who received 2 years of treatment with glucosamine sulfate or a placebo. Glucosamine was no better than placebo in terms of effects on pain, joint function, or joint structure (assessed as joint space narrowing).
One study with 162 participants has evaluated chondroitin for hand osteoarthritis. In this 6-month trial, hand pain decreased and hand function improved to a greater extent in the chondroitin group than the placebo group.
A few studies have looked at whether glucosamine or chondroitin or the combination can have beneficial effects on joint structure in people with OA. Some but not all of these studies found evidence that chondroitin or a glucosamine-chondroitin combination might help, but the improvements seen in most studies may be too small to make a difference to patients.
One study evaluated the short-term effect of an oral combination of hyaluronic acid, chondroitin sulfate, and keratin matrix on early symptomatic knee osteoarthritis. Forty patients were treated for 1 month and were allowed to take analgesics or NSAIDs if necessary. At 2 months, the mean reduction of the WOMAC score was 36% (p<0.001), and the mean reduction of the WOMAC pain score was 40% (p<0.001). Only two patients reported a sporadic need to take analgesics; no patient reported any side effect during the study period. This data demonstrates that the oral combination of hyaluronic acid, chondroitin sulfate, and keratin matrix is safe, well tolerated, and shows a rapid action in reducing pain and improving joint function and stiffness in early symptomatic knee osteoarthritis. This study was small (n=40) and uncontrolled in design, limiting the strength of its conclusions.
The 2019 guideline for osteoarthritis management from the American College of Rheumatology and the Arthritis Foundation conditionally recommends chondroitin for patients with hand osteoarthritis, based on the evidence reviewed. Overall, the evidence suggests that glucosamine and chondroitin are generally effective and well-tolerated, particularly for managing osteoarthritis and joint pain. Consistent dosing strategies and favorable safety profiles across a diverse range of studies support their continued use in clinical practice, but further research is needed related to other disease states.
Studies of glucosamine for pain in knee OA have had conflicting results. Some, including a major National Institutes of Health (NIH)-sponsored study, found little or no evidence that glucosamine can relieve pain, but several other studies indicated that it can.
Hyaluronic acid is reduced in adult skin compared with juvenile skin, alongside downregulation of CD44, HAS1, HAS2 and RHAMM. Within photoaged skin there are similarly decreased levels of HAS1, CD44, and RHAMM, but also an increase of low mass HA.
One RCT in 65 females with periocular wrinkles showed significant improvement in skin hydration and elasticity versus placebo after 60 days of using 0.1% sodium hyaluronate formulations of different molecular weights. Moreover, two of the lowest molecular weight HA formulations led to significantly reduced wrinkle depth; the authors speculate that this may be explained by the greater anti-inflammatory and penetration potential of LMW-HA.
Hyaluronic acid (HA) is a linear polysaccharide classified as a glycosaminoglycan. As a highly hygroscopic molecule, it has an exceptional ability to bind water, which has been described to promote skin hydration and enhance elasticity.
Glycosaminoglycans are a well-recognized skincare target due to their high endogenous expression in skin, pleiotropic biological action, and attenuated expression/activity within aged skin.
Research on GAG-based wound healing materials is largely preclinical. GAGs and GAG-based biomaterial approaches have been widely explored to promote in situ tissue regeneration and repair by regulating the wound microenvironment, accelerating re-epithelialization, and controlling ECM remodeling. However, most approaches remain unacceptable for clinical applications.
Low molecular weight HA (LMWHA) induces inflammation to stimulate angiogenesis and tissue regeneration, whereas high molecular weight HA (HMWHA) regulates the recruitment of inflammatory cells, production of cytokines, and migration of stem cells. GAGs facilitate the interaction between ECM scaffolds and cell receptors by modulating cell–cell and cell–matrix signaling and adhesion, thereby promoting cell adhesion, migration, and proliferation. GAGs facilitate the constant renewal of the ECM to uphold its organizational, structural, and functional integrity by interacting with collagens and glycoproteins.
Unlike dietary GAG supplements, the clinical evidence for pharmaceutical-grade heparin (a GAG) is definitive and well-established. Heparin is a life-saving compound, crucial for procedures such as treatment of deep venous thrombosis (DVT), pulmonary embolism (PE), and acute coronary syndrome (ACS), as well as for anticoagulation in surgery, interventional cardiology, and hemodialysis. Low molecular weight heparins (LMWHs) are depolymerized heparin derivatives developed in the 1980s, with pharmacologic profiles distinct from UFH. These applications represent among the strongest bodies of clinical evidence of any GAG in medicine, but they are pharmaceutical uses rather than dietary supplement uses.
The following dosages are reported specifically as used in referenced clinical studies and trials:
It should be noted that dosage ranges across studies vary and that preparation quality matters significantly. Taking chondroitin sulfate by mouth seems to provide some relief from osteoarthritis pain and improve function. High quality, pharmaceutical-grade products have shown the most benefit. Chondrosulf (IBSA Institut Biochimique SA), Chondrosan (Bioiberica, S.A.), and Structum (Laboratoires Pierre Fabre) are examples of these products.
A controlled trial of 24 months of glucosamine, chondroitin, their combination, or celecoxib vs. placebo in 662 patients with knee osteoarthritis found that rates of adverse events were similar across treatment groups and no liver-related serious adverse event occurred.
A review of the structure, pharmacokinetics, possible mechanisms of action, clinical efficacy and safety of glucosamine and chondroitin as therapy for osteoarthritis concluded that, other than a possible interaction with warfarin, no serious adverse events have been linked to long-term use of glucosamine and chondroitin.
Interactions of glucosamine with warfarin and acenocoumarol have been described. This is a clinically important interaction given the prevalence of anticoagulant use in the OA patient population.
Asthma has reportedly been exacerbated by the use of a glucosamine–chondroitin supplement for osteoarthritis.
There are no dietary sources of glucosamine, and commercially available glucosamine is derived from shellfish. Individuals with shellfish allergies should therefore consider the source of glucosamine-based supplements.
Pharmaceutical heparin, as a GAG, carries well-documented risks in clinical use. Uterine contractions due to heparin are described as a side effect of intravenous administration of high-dose heparin for the treatment of vein thrombosis to a 32-year-old multigravida in the thirty-second week of pregnancy. These risks are relevant to pharmaceutical heparin administration, not to dietary GAG supplementation.
Clinical relevance of molecular mechanisms studied in vitro is questionable because of higher concentrations of tested substances in vitro than in vivo. Much of the mechanistic rationale for GAG supplementation is derived from in vitro work conducted at concentrations not necessarily achievable through oral supplementation.
In two studies of glucosamine sulphate, both funded by the manufacturer of an oral powder product, the need for knee arthroplasty was reduced from 14.5% to 6.3% at 8 years' follow-up. For other preparations of glucosamine, chondroitin, and combination therapy, there was less evidence to support a clinical effect. This highlights the importance of funding sources and product quality in interpreting the evidence base.
Condiciones de salud que Glicosaminoglicanos puede ayudar a apoyar.
Glycosaminoglycans (GAGs) are the primary structural polysaccharides of articular cartilage, including chondroitin sulfate, hyaluronic acid, and keratan sulfate, trapping water to provide compressive resistance. Their loss is the defining biochemical event in OA. Supplemental GAGs (chondroitin sulfate, hyaluronic acid, N-acetylglucosamine) have been validated in clinical trials. A 2022 MDPI nutraceutical review confirmed exogenous GAGs stimulate anabolic cartilage metabolism and delay catabolic cartilage degradation.
Glycosaminoglycans (GAGs), including chondroitin sulfate, hyaluronic acid, and heparan sulfate, are structural components of cartilage and synovial fluid with established roles in osteoarthritis chronic pain management. Supplementation with GAG-rich preparations from bovine or marine sources reduces joint pain in OA. Traditional use includes cartilage-rich foods in multiple cultures.
Glycosaminoglycans (GAGs) are the primary structural polysaccharides of connective tissue extracellular matrix, including hyaluronic acid, chondroitin sulfate, dermatan sulfate, and keratan sulfate. They maintain water retention, flexibility, and compression resistance in cartilage, tendons, ligaments, and skin. Supplemental GAGs have established roles in supporting connective tissue matrix integrity.
Glycosaminoglycans (GAGs) are long-chain polysaccharides—including chondroitin sulfate, hyaluronic acid, heparan sulfate, and keratan sulfate—that form the structural backbone of cartilage and synovial fluid. They are essential for joint lubrication, shock absorption, and cartilage integrity. Clinical supplements of specific GAGs (chondroitin, hyaluronic acid) have documented evidence for improving joint mobility in osteoarthritis.
Glycosaminoglycans (GAGs) directly address the primary recognized pathology of IC/BPS — dysfunction of the bladder's protective GAG urothelial layer. Intravesical GAG therapies (hyaluronic acid, chondroitin sulfate) show up to 85% improvement rates, and oral multi-agent GAG supplements produced significant symptom reduction in a 252-patient uncontrolled trial (Theoharides et al., Can J Urol 2008).
Glycosaminoglycans (GAGs), including hyaluronic acid and chondroitin sulfate, are key components of the ECM involved in scar formation and remodeling. Evidence from wound healing and scar models supports their role in promoting organized collagen deposition and reducing pathological scarring.
Glycosaminoglycans (GAGs—hyaluronic acid, chondroitin sulfate, dermatan sulfate) are core structural components of skin dermis providing hydration and elasticity. Declining GAG content with aging drives skin sagging and wrinkling. Oral hyaluronic acid supplementation (the most clinically studied GAG) has shown wrinkle reduction confirmed in meta-analyses of multiple RCTs.
Glycosaminoglycans (GAGs) including hyaluronic acid and chondroitin sulfate are structural components of the dermal ECM that regulate collagen fibrillogenesis and maintain skin hydration and elasticity. Their depletion with aging drives loss of skin elasticity; supplementation with GAGs or GAG precursors with collagen has clinical RCT evidence for improved skin elasticity.
Sistemas corporales que Glicosaminoglicanos puede ayudar a apoyar.
Volver